Venture Visionary Partners LLC Decreases Stake in GSK plc (NYSE:GSK)

Venture Visionary Partners LLC decreased its holdings in GSK plc (NYSE:GSK) by 4.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,880 shares of the pharmaceutical company’s stock after selling 300 shares during the quarter. Venture Visionary Partners LLC’s holdings in GSK were worth $240,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1832 Asset Management L.P. lifted its position in GSK by 9.1% during the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after purchasing an additional 257 shares during the last quarter. Boltwood Capital Management grew its position in GSK by 2.5% in the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after acquiring an additional 270 shares in the last quarter. J.W. Cole Advisors Inc. raised its position in GSK by 4.7% during the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after purchasing an additional 271 shares during the period. First Affirmative Financial Network lifted its stake in shares of GSK by 4.7% in the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after purchasing an additional 283 shares during the last quarter. Finally, Chapin Davis Inc. boosted its holdings in shares of GSK by 2.2% in the 1st quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock worth $610,000 after purchasing an additional 300 shares during the period. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Jefferies Financial Group raised their price target on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Barclays raised shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Finally, Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, GSK currently has a consensus rating of “Buy” and an average price target of $50.00.

Insider Activity at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

GSK Stock Down 0.1 %

Shares of NYSE:GSK opened at $37.96 on Thursday. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The business’s 50 day moving average is $41.27 and its 200 day moving average is $41.19. The stock has a market cap of $78.67 billion, a P/E ratio of 13.75, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. Sell-side analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a dividend of $0.3843 per share. The ex-dividend date of this dividend was Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 4.05%. GSK’s dividend payout ratio (DPR) is currently 55.80%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.